NCT02852005View on ClinicalTrials.gov

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

August 29, 2018

Study Completion Date

October 29, 2019

Conditions
HIV Infections
Interventions
BIOLOGICAL

MVA/HIV62B vaccine

1×10\^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid

BIOLOGICAL

AIDSVAX B/E vaccine

600 mcg/mL dose to be administered as a 1 mL IM injection in the deltoid

BIOLOGICAL

Placebo

Sodium Chloride for Injection USP, 0.9% to be administered as a 1 mL IM injection in the deltoid

Trial Locations (9)

1

ACSA CRS, Iquitos

14642

University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester

30030

The Hope Clinic of the Emory Vaccine Center CRS, Decatur

35294

Alabama CRS, Birmingham

94143

Bridge HIV CRS, San Francisco

02115-6110

Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston

10032-3732

Columbia P&S CRS, New York

98109-1024

Seattle Vaccine and Prevention CRS, Seattle

04 - 15063

Barranco CRS, Lima

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02852005 - Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205 | Biotech Hunter | Biotech Hunter